Sinusoidal communication in liver fibrosis and regeneration

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 608-617

  Marrone, Giusi ^a   Shah, Vijay H ^b   Gracia Sancho, Jordi ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MAYO CLINIC   (United States)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Cirrhosis; Hepatic stellate cells; Hepatocytes; HSC; Ischemia reperfusion; Kupffer cells; Liver sinusoidal endothelial cells; LSEC; Portal hypertension; Regeneration; Transplantation

Indexed keywords

CELL COMMUNICATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; LIVER SINUSOID; LIVER SINUSOIDAL ENDOTHELIAL CELL; LIVER TRANSPLANTATION; NONHUMAN; PARACRINE SIGNALING; PARTIAL HEPATECTOMY; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; LIVER; LIVER RESECTION;

HEPATECTOMY; HEPATOCYTES; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER REGENERATION;

EID: 84991110311     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.04.018     Document Type: Review

References (97)

1. [1] Braet, F., Wisse, E., Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol, 1, 2002, 1.
2. [2] Cogger, V.C., Warren, A., Fraser, R., Ngu, M., McLean, A.J., le Couteur, D.G., Hepatic sinusoidal pseudocapillarization with aging in the non-human primate. Exp Gerontol 38 (2003), 1101–1107.
3. [3] McLean, A.J., Cogger, V.C., Chong, G.C., Warren, A., Markus, A.M., Dahlstrom, J.E., et al. Age-related pseudocapillarization of the human liver. J Pathol 200 (2003), 112–117.
4. [4] Schaffner, F., Poper, H., Capillarization of hepatic sinusoids in man. Gastroenterology 44 (1963), 239–242.
5. [5] Urashima, S., Tsutsumi, M., Nakase, K., Wang, J.S., Takada, A., Studies on capillarization of the hepatic sinusoids in alcoholic liver disease. Alcohol Alcohol Suppl 1B (1993), 77–84.
6. [6] Xu, B., Broome, U., Uzunel, M., Nava, S., Ge, X., Kumagai-Braesch, M., et al. Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. Am J Pathol 163 (2003), 1275–1289.
7. [7] Geraud, C., Evdokimov, K., Straub, B.K., Peitsch, W.K., Demory, A., Dorflinger, Y., et al. Unique cell type-specific junctional complexes in vascular endothelium of human and rat liver sinusoids. PLoS One, 7, 2012, e34206.
8. [8] Essani, N.A., McGuire, G.M., Manning, A.M., Jaeschke, H., Differential induction of mRNA for ICAM-1 and selectins in hepatocytes, Kupffer cells and endothelial cells during endotoxemia. Biochem Biophys Res Commun 211 (1995), 74–82.
9. [9] DeLeve, L.D., Wang, X., Hu, L., McCuskey, M.K., McCuskey, R.S., Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol 287 (2004), G757–G763.
10. [10] Friedman, S.L., Roll, F.J., Boyles, J., Bissell, D.M., Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 82 (1985), 8681–8685.
11. [11] Sato, M., Suzuki, S., Senoo, H., Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 28 (2003), 105–112.
12. [12] Pinzani, M., Gentilini, P., Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 19 (1999), 397–410.
13. [13] Wake, K., Structure of the sinusoidal wall in the liver. Wisse, E., Knook, D.L., Wake, K., (eds.) Cells of the hepatic sinusoid, 1995, The Kupffer Cell Foundation, Leiden, 241–246.
14. [14] Bilzer, M., Roggel, F., Gerbes, A.L., Role of Kupffer cells in host defense and liver disease. Liver Int 26 (2006), 1175–1186.
15. [15] Liaskou, E., Wilson, D.V., Oo, Y.H., Innate immune cells in liver inflammation. Mediators Inflamm, 2012, 2012, 949157.
16. [16] McCuskey, R.S., Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver 20 (2000), 3–7.
17. [17] Malhi, H., Guicciardi, M.E., Gores, G.J., Hepatocyte death: a clear and present danger. Physiol Rev 90 (2010), 1165–1194.
18. [18] Wells, R.G., The role of matrix stiffness in regulating cell behavior. Hepatology 47 (2008), 1394–1400.
19. [19] March, S., Hui, E.E., Underhill, G.H., Khetani, S., Bhatia, S.N., Microenvironmental regulation of the sinusoidal endothelial cell phenotype in vitro. Hepatology 50 (2009), 920–928.
20. [20] Friedman, S.L., Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1 (2004), 98–105.
21. [21] Pinzani, M., Rosselli, M., Zuckermann, M., Liver cirrhosis. Best Pract Res Clin Gastroenterol 25 (2011), 281–290.
22. [22] Garcia-Pagan, J.C., Gracia-Sancho, J., Bosch, J., Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 57 (2012), 458–461.
23. [23] Gracia-Sancho, J., Lavina, B., Rodriguez-Vilarrupla, A., Garcia-Caldero, H., Bosch, J., Garcia-Pagan, J.C., Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 47 (2007), 220–227.
24. [24] Steib, C.J., Gerbes, A.L., Bystron, M., op den Winkel, M., Hartl, J., Roggel, F., et al. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol 47 (2007), 228–238.
25. [25] Said, A., Lucey, M.R., Liver transplantation: an update 2008. Curr Opin Gastroenterol 24 (2008), 339–345.
26. [26] DeLeve, L.D., The hepatic sinusoidal endothelial cell: morphology, function, and pathobiology. Arias, I.M., (eds.) The liver: biology and pathobiology, 5th ed., 2009, Wiley & Sons, Hokoben, 371–388.
27. [27] Jarnagin, W.R., Rockey, D.C., Koteliansky, V.E., Wang, S.S., Bissell, D.M., Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 127 (1994), 2037–2048.
28. [28] Canbay, A., Feldstein, A.E., Higuchi, H., Werneburg, N., Grambihler, A., Bronk, S.F., et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38 (2003), 1188–1198.
29. [29] Jiang, J.X., Mikami, K., Venugopal, S., Li, Y., Torok, N.J., Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol 51 (2009), 139–148.
30. [30] McGuire, R.F., Bissell, D.M., Boyles, J., Roll, F.J., Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver. Hepatology 15 (1992), 989–997.
31. [31] Yamane, A., Seetharam, L., Yamaguchi, S., Gotoh, N., Takahashi, T., Neufeld, G., et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 9 (1994), 2683–2690.
32. [32] Zhang, D.W., Zhao, Y.X., Wei, D., Li, Y.L., Zhang, Y., Wu, J., et al. HAb18G/CD147 promotes activation of hepatic stellate cells and is a target for antibody therapy of liver fibrosis. J Hepatol 57 (2012), 1283–1291.
33. [33] Yan, Z., Qu, K., Zhang, J., Huang, Q., Qu, P., Xu, X., et al. CD147 promotes liver fibrosis progression via VEGF-A/VEGFR2 signalling-mediated cross-talk between hepatocytes and sinusoidal endothelial cells. Clin Sci (Lond) 129 (2015), 699–710.
34. [34] Di Pascoli, M., Divi, M., Rodriguez-Vilarrupla, A., Rosado, E., Gracia-Sancho, J., Vilaseca, M., et al. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 58 (2013), 904–910.
35. [35] Guillaume, M., Rodriguez-Vilarrupla, A., Gracia-Sancho, J., Rosado, E., Mancini, A., Bosch, J., et al. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. J Hepatol 58 (2013), 240–246.
36. [36] Bannert, K., Kuhla, A., Abshagen, K., Vollmar, B., Anti-apoptotic therapeutic approaches in liver diseases: do they really make sense?. Apoptosis 19 (2014), 1243–1253.
37. [37] Wells, R.G., Cellular sources of extracellular matrix in hepatic fibrosis. Clin Liver Dis 12 (2008), 759–768 viii.
38. [38] Myers, P.R., Tanner, M.A., Vascular endothelial cell regulation of extracellular matrix collagen: role of nitric oxide. Arterioscler Thromb Vasc Biol 18 (1998), 717–722.
39. [39] Ford, A.J., Jain, G., Rajagopalan, P., Designing a fibrotic microenvironment to investigate changes in human liver sinusoidal endothelial cell function. Acta Biomater 24 (2015), 220–227.
40. [40] Li, Z., Dranoff, J.A., Chan, E.P., Uemura, M., Sevigny, J., Wells, R.G., Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 46 (2007), 1246–1256.
41. [41] Olsen, A.L., Bloomer, S.A., Chan, E.P., Gaca, M.D., Georges, P.C., Sackey, B., et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol 301 (2011), G110–G118.
42. [42] Gortzen, J., Schierwagen, R., Bierwolf, J., Klein, S., Uschner, F.E., van der Ven, P.F., et al. Interplay of matrix stiffness and c-SRC in hepatic fibrosis. Front Physiol, 6, 2015, 359.
43. [43] Halfon, P., Bourliere, M., Penaranda, G., Deydier, R., Renou, C., Botta-Fridlund, D., et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol, 4, 2005, 6.
44. [44] Tangkijvanich, P., Kongtawelert, P., Pothacharoen, P., Mahachai, V., Suwangool, P., Poovorawan, Y., Serum hyaluronan: a marker of liver fibrosis in patients with chronic liver disease. Asian Pac J Allergy Immunol 21 (2003), 115–120.
45. [45] Deaciuc, I.V., Bagby, G.J., Lang, C.H., Spitzer, J.J., Hyaluronic acid uptake by the isolated, perfused rat liver: an index of hepatic sinusoidal endothelial cell function. Hepatology 17 (1993), 266–272.
46. [46] Muriel, P., Escobar, Y., Kupffer cells are responsible for liver cirrhosis induced by carbon tetrachloride. J Appl Toxicol 23 (2003), 103–108.
47. [47] Nieto, N., Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology 44 (2006), 1487–1501.
48. [48] Cubero, F.J., Nieto, N., Ethanol and arachidonic acid synergize to activate Kupffer cells and modulate the fibrogenic response via tumor necrosis factor alpha, reduced glutathione, and transforming growth factor beta-dependent mechanisms. Hepatology 48 (2008), 2027–2039.
49. [49] Castera, L., Pinzani, M., Bosch, J., Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 56 (2012), 696–703.
50. [50] DeLeve, L.D., Wang, X., Guo, Y., Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 48 (2008), 920–930.
51. [51] Xie, G., Wang, X., Wang, L., Wang, L., Atkinson, R.D., Kanel, G.C., et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology 142 (2012), 918–927.
52. [52] Marrone, G., Russo, L., Rosado, E., Hide, D., Garcia-Cardena, G., Garcia-Pagan, J.C., et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol 58 (2013), 98–103.
53. [53] Marrone, G., Maeso-Díaz, R., Garcia-Cardena, G., Garcia-Pagan, J.C., Bosch, J., Gracia-Sancho, J., KLF2 exerts anti-fibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 64 (2015), 1434–1443.
54. [54] Zafra, C., Abraldes, J.G., Turnes, J., Berzigotti, A., Fernandez, M., Garca-Pagan, J.C., et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126 (2004), 749–755.
55. [55] Abraldes, J.G., Rodriguez-Vilarrupla, A., Graupera, M., Zafra, C., Garcia-Caldero, H., Garcia-Pagan, J.C., et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl(4) cirrhotic rats. J Hepatol 46 (2007), 1040–1046.
56. [56] Trebicka, J., Hennenberg, M., Laleman, W., Shelest, N., Biecker, E., Schepke, M., et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46 (2007), 242–253.
57. [57] Trebicka, J., Hennenberg, M., Odenthal, M., Shir, K., Klein, S., Granzow, M., et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53 (2010), 702–712.
58. [58] Gracia-Sancho, J., Russo, L., Garcia-Caldero, H., Garcia-Pagan, J.C., Garcia-Cardena, G., Bosch, J., Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut 60 (2011), 517–524.
59. [59] Klein, S., Klosel, J., Schierwagen, R., Korner, C., Granzow, M., Huss, S., et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 92 (2012), 1440–1450.
60. [60] Kumar, S., Grace, N.D., Qamar, A.A., Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci 59 (2014), 1958–1965.
61. [61] Souk, K., Al-Badri, M., Azar, S.T., The safety and benefit of statins in liver cirrhosis: a review. Exp Clin Endocrinol Diabetes 123 (2015), 577–580.
62. [62] Bosch, J., Forns, X., Therapy. Statins and liver disease: from concern to ’wonder’ drugs?. Nat Rev Gastroenterol Hepatol 12 (2015), 320–321.
63. [63] Abraldes, J.G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150 (2016), 1160–1170.
64. [64] Bellis, L., Berzigotti, A., Abraldes, J.G., Moitinho, E., Garcia-Pagan, J.C., Bosch, J., et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 37 (2003), 378–384.
65. [65] Fiorucci, S., Antonelli, E., Brancaleone, V., Sanpaolo, L., Orlandi, S., Distrutti, E., et al. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 39 (2003), 932–939.
66. [66] Bosch, J., Decreasing hepatic vascular tone by liver-specific NO donors: wishful thinking or a promising reality?. J Hepatol 39 (2003), 1072–1075.
67. [67] Berzigotti, A., Bellot, P., DeGottardi, A., Garcia-Pagan, J.C., Gagnon, C., Spenard, J., et al. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Am J Gastroenterol, 2009.
68. [68] Ray, K., Liver: Sussing out statins in cirrhosis–KLF2 is the key. Nat Rev Gastroenterol Hepatol, 12, 2015, 64.
69. [69] Hide, D., Ortega-Ribera, M., Garcia-Pagan, J.C., Peralta, C., Bosch, J., Gracia-Sancho, J., Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy. Sci Rep, 6, 2016, 22107.
70. [70] Lemoinne, S., Cadoret, A., Rautou, P.E., El, M.H., Ratziu, V., Corpechot, C., et al. Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology 61 (2015), 1041–1055.
71. [71] Wang, R., Ding, Q., Yaqoob, U., de Assuncao, T.M., Verma, V.K., Hirsova, P., et al. Exosome adherence and internalization by hepatic stellate cells triggers sphingosine 1-phosphate-dependent migration. J Biol Chem 290 (2015), 30684–30696.
72. [72] Nelson, D.R., Tu, Z., Soldevila-Pico, C., Abdelmalek, M., Zhu, H., Xu, Y.L., et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38 (2003), 859–868.
73. [73] Lebrec, D., Thabut, D., Oberti, F., Perarnau, J.M., Condat, B., Barraud, H., et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 138 (2010), 1755–1762.
74. [74] Van Wagner, L.B., Koppe, S.W., Brunt, E.M., Gottstein, J., Gardikiotes, K., Green, R.M., et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 10 (2011), 277–286.
75. [75] Scorletti, E., Bhatia, L., McCormick, K.G., Clough, G.F., Nash, K., Hodson, L., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome∗ study. Hepatology 60 (2014), 1211–1221.
76. [76] Reverter, E., Mesonero, F., Seijo, S., Martinez, J., Abraldes, J.G., Penas, B., et al. Effects of sapropterin on portal and systemic hemodynamics in patients with cirrhosis and portal hypertension: a bicentric double-blind placebo-controlled study. Am J Gastroenterol 110 (2015), 985–992.
77. [77] Ding, B.S., Nolan, D.J., Butler, J.M., James, D., Babazadeh, A.O., Rosenwaks, Z., et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468 (2010), 310–315.
78. [78] Ding, B.S., Cao, Z., Lis, R., Nolan, D.J., Guo, P., Simons, M., et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 505 (2014), 97–102.
79. [79] Mao, S.A., Glorioso, J.M., Nyberg, S.L., Liver regeneration. Transl Res 163 (2014), 352–362.
80. [80] Widmann, J.J., Fahimi, H.D., Proliferation of mononuclear phagocytes (Kupffer cells) and endothelial cells in regenerating rat liver. A light and electron microscopic cytochemical study. Am J Pathol 80 (1975), 349–366.
81. [81] Abshagen, K., Eipel, C., Kalff, J.C., Menger, M.D., Vollmar, B., Loss of NF-kappaB activation in Kupffer cell-depleted mice impairs liver regeneration after partial hepatectomy6. Am J Physiol Gastrointest Liver Physiol 292 (2007), G1570–G1577.
82. [82] Xu, C.S., Jiang, Y., Zhang, L.X., Chang, C.F., Wang, G.P., Shi, R.J., et al. The role of Kupffer cells in rat liver regeneration revealed by cell-specific microarray analysis. J Cell Biochem 113 (2012), 229–237.
83. [83] Taniguchi, E., Sakisaka, S., Matsuo, K., Tanikawa, K., Sata, M., Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 49 (2001), 121–130.
84. [84] Sato, T., El-Assal, O.N., Ono, T., Yamanoi, A., Dhar, D.K., Nagasue, N., Sinusoidal endothelial cell proliferation and expression of angiopoietin/Tie family in regenerating rat liver. J Hepatol 34 (2001), 690–698.
85. [85] Mabuchi, A., Mullaney, I., Sheard, P.W., Hessian, P.A., Mallard, B.L., Tawadrous, M.N., et al. Role of hepatic stellate cell/hepatocyte interaction and activation of hepatic stellate cells in the early phase of liver regeneration in the rat. J Hepatol 40 (2004), 910–916.
86. [86] Roskams, T., Relationships among stellate cell activation, progenitor cells, and hepatic regeneration. Clin Liver Dis 12 (2008), 853–860 ix.
87. [87] Wang, L., Wang, X., Wang, L., Chiu, J.D., Van de Ven, G., Gaarde, W.A., et al. Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells. Gastroenterology 143 (2012), 1555–1563.
88. [88] DeLeve, L.D., Liver sinusoidal endothelial cells and liver regeneration. J Clin Invest 123 (2013), 1861–1866.
89. [89] Katagiri, H., Kushida, Y., Nojima, M., Kuroda, Y., Wakao, S., Ishida, K., et al. A distinct subpopulation of bone marrow mesenchymal stem cells, muse cells, directly commit to the replacement of liver components. Am J Transplant, 10, 2015.
90. [90] Gupta, S., Rajvanshi, P., Sokhi, R., Slehria, S., Yam, A., Kerr, A., et al. Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium. Hepatology 29 (1999), 509–519.
91. [91] Wang, L., Wang, X., Xie, G., Wang, L., Hill, C.K., DeLeve, L.D., Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats. J Clin Invest 122 (2012), 1567–1573.
92. [92] Mochida, S., Ishikawa, K., Inao, M., Shibuya, M., Fujiwara, K., Increased expressions of vascular endothelial growth factor and its receptors, flt-1 and KDR/flk-1, in regenerating rat liver. Biochem Biophys Res Commun 226 (1996), 176–179.
93. [93] Hu, J., Srivastava, K., Wieland, M., Runge, A., Mogler, C., Besemfelder, E., et al. Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. Science 343 (2014), 416–419.
94. [94] Benten, D., Kumaran, V., Joseph, B., Schattenberg, J., Popov, Y., Schuppan, D., et al. Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. Hepatology 42 (2005), 1072–1081.
95. [95] Fernandez-Mena, C., Almagro, J., Puerro, M., Quintana, A., Hidalgo, J., Bañares, R., et al. Effects of myeloid cell-selective deficiency of IL-6 for liver regeneration after partial hepatectomy (PH) in mice. Hepatology, 62, 2016, 848A.
96. [96] Illa, X., Vila, S., Yeste, J., Peralta, C., Gracia-Sancho, J., Villa, R., A novel modular bioreactor to in vitro study the hepatic sinusoid. PLoS ONE, 2014, 10.1371/journal.pone.0111864.
97. [97] Prodanov, L., Jindal, R., Bale, S.S., Hegde, M., McCarty, W.J., Golberg, I., et al. Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol Bioeng 113 (2016), 241–246.